What are Halozyme Therapeutics's profit margins?

Halozyme Therapeutics (HALO) runs a 82.8% gross margin and a 59.3% operating margin, with a 47.9% net margin.

Where do Halozyme Therapeutics's ratios come from?

Every ratio is computed from Halozyme Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.

Halozyme Therapeutics HALO Ratios & Valuation

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY

Simplified Detailed

	FY'25	FY'24	FY'23	FY'22
Profitability
Gross margin	83.6%-0.7pp	84.3%+7.5pp	76.8%-2.1pp	78.9%-2.7pp
Free cash flow margin	46.2%0.0pp	46.1%+1.1pp	45%+9.4pp	35.6%-31.6pp
Efficiency
Asset turnover	0.6×+0.1×	0.5×+0.1×	0.5×0.0×	0.4×-0.1×
Inventory turnover	6×—	——	——	1.8×+0.4×
Liquidity
Current ratio	4.7×-3.1×	7.8×+1.2×	6.6×+1.0×	5.7×-2.3×
Quick ratio	4.5×-2.9×	7.4×+0.8×	6.6×+1.8×	4.9×-2.6×
Cash ratio	0.8×-0.1×	0.8×-0.2×	1.1×-0.7×	1.8×+0.8×
Leverage
Debt-to-equity	44.6×+40.4×	4.2×-14.1×	18.3×+9.2×	9.1×+4.6×
Debt-to-assets	0.9×+0.1×	0.7×-0.1×	0.9×0.0×	0.8×0.0×
Per Share
Book value per share	$0.39-86.0%	$2.81+350%	$0.62-48.3%	$1.21-10.0%
Valuation
Market capitalization	$7.91B+30.1%	$6.08B+27.5%	$4.77B-38.0%	$7.7B+39.1%
Enterprise value	$9.96B+32.7%	$7.5B+21.4%	$6.18B-31.3%	$9B+43.0%
Price / sales	5.7×-0.3×	6×+0.2×	5.8×-5.9×	11.7×-0.8×
Price / book	162.1×+145×	16.7×-40.2×	56.9×+11.6×	45.3×+17.2×
EV / sales	7.1×-0.3×	7.4×-0.1×	7.5×-6.2×	13.6×-0.6×
Free cash flow yield	8.1%+0.4pp	7.7%-0.1pp	7.8%+4.8pp	3.1%-2.3pp

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Ask your AI about Halozyme Therapeutics.

Connect your AI assistant and get a quick read on the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What are Halozyme Therapeutics's profit margins?: Halozyme Therapeutics (HALO) runs a 82.8% gross margin and a 59.3% operating margin, with a 47.9% net margin.
Where do Halozyme Therapeutics's ratios come from?: Every ratio is computed from Halozyme Therapeutics's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.